214 related articles for article (PubMed ID: 33280191)
1. CREB3L1 overexpression as a potential diagnostic marker of Philadelphia chromosome-negative myeloproliferative neoplasms.
Morishita S; Yasuda H; Yamawaki S; Kawaji H; Itoh M; Edahiro Y; Imai M; Kogo Y; Tsuneda S; Ohsaka A; Hayashizaki Y; Ito M; Araki M; Komatsu N
Cancer Sci; 2021 Feb; 112(2):884-892. PubMed ID: 33280191
[TBL] [Abstract][Full Text] [Related]
2. Clinical and biological relevance of CREB3L1 in Philadelphia chromosome-negative myeloproliferative neoplasms.
De Marchi F; Okuda M; Morishita S; Imai M; Baba T; Horino M; Mori Y; Furuya C; Ogata S; Yang Y; Ando J; Ando M; Araki M; Komatsu N
Leuk Res; 2022 Aug; 119():106883. PubMed ID: 35689957
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
[TBL] [Abstract][Full Text] [Related]
4. Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Sankar K; Stein BL; Rampal RK
Cancer Treat Res; 2019; 179():159-178. PubMed ID: 31317487
[TBL] [Abstract][Full Text] [Related]
5. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).
Michiels JJ; Thiele J
Int J Hematol; 2002 Aug; 76(2):133-45. PubMed ID: 12215011
[TBL] [Abstract][Full Text] [Related]
6. [Thrombocytosis versus thrombocythemia--differential diagnosis of elevated platelet count].
Thiele J; Kvasnicka HM
Pathologe; 2000 Jan; 21(1):31-8. PubMed ID: 10663667
[TBL] [Abstract][Full Text] [Related]
7. Rare Case of Accelerated-Phase Chronic Myeloid Leukemia Diagnosed During Treatment for JAK2 V617F-Positive Primary Myelofibrosis.
Ryu J; Chu D; Park B; Kim M; Cho YU; Hwang SH; Jang S; Seo EJ; Lee JH; Park CJ
Lab Med; 2022 Nov; 53(6):e140-e144. PubMed ID: 35243502
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms.
Bisen A; Claxton DF
Adv Exp Med Biol; 2013; 779():179-96. PubMed ID: 23288640
[TBL] [Abstract][Full Text] [Related]
9. Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.
Yung Y; Lee E; Chu HT; Yip PK; Gill H
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33440869
[TBL] [Abstract][Full Text] [Related]
10. The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview.
Tefferi A
Mayo Clin Proc; 1998 Dec; 73(12):1177-84. PubMed ID: 9868417
[TBL] [Abstract][Full Text] [Related]
11. Philadelphia Chromosome Positive Chronic Myelogenous Leukemia Blastic Crisis in A Patient with Unusual Primary Myelofibrosis Characteristics; A Case Report.
Razmara Lak E; Sharifzadeh S; Ramzi M; Mokhtari M; Asadpouri R; Abedi E; Tamaddon G
Cardiovasc Hematol Agents Med Chem; 2023 Jun; ():. PubMed ID: 37317905
[TBL] [Abstract][Full Text] [Related]
12. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
13. Chronic myeloid leukemia (CML) evolves from Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) with unexpected frequency.
Hochman MJ; Smith BD; Karantanos T; Braunstein EM; Gojo I; Jain T; Streiff MB; Moliterno AR; DeZern AE
Int J Hematol; 2023 Mar; 117(3):456-462. PubMed ID: 36181657
[TBL] [Abstract][Full Text] [Related]
14. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
15. Unique Case of Myeloproliferative Neoplasm with Two Rare Clonal Abnormalities: Rare JAK2 Exon 12 Mutation and Rare e14a3 (b3a3) BCR/ABL Fusion Transcript.
Swaminathan M; Patel KP; Huynh-Lu J; Tang G; Zuo Z; Miranda R; Verstovsek S
Acta Haematol; 2019; 141(1):23-27. PubMed ID: 30463063
[TBL] [Abstract][Full Text] [Related]
16. Molecular genetic evaluation of myeloproliferative neoplasms.
Azzato EM; Bagg A
Int J Lab Hematol; 2015 May; 37 Suppl 1():61-71. PubMed ID: 25976962
[TBL] [Abstract][Full Text] [Related]
17. Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities.
Coltro G; Loscocco GG; Vannucchi AM
Int Rev Cell Mol Biol; 2021; 365():1-69. PubMed ID: 34756241
[TBL] [Abstract][Full Text] [Related]
18. [New molecular markers within the chronic myeloproliferative disorders. I: the PRV-1 gene].
Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
Ugeskr Laeger; 2006 Sep; 168(39):3295-9. PubMed ID: 17032591
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients.
Ebid GT; Ghareeb M; Salaheldin O; Kamel MM
Int J Clin Exp Pathol; 2015; 8(9):11555-9. PubMed ID: 26617890
[TBL] [Abstract][Full Text] [Related]
20. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
Brière J
Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
